| Ytd | -49.14% | |
| 1y | -31.52% |
| Open | 1.72 | Prev Close | 1.75 | Low | 1.72 | High | 1.76 | Mkt Cap | 34.43M |
| Vol | 131.95K | Avg Vol | 1.08M | EPS | -1.71 | P/E | -1.02 | Forward P/E | -2.77 |
| Beta | 1.19 | Short Ratio | 6.21 | Inst. Own | 8.83% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-18 | 50-d Avg | 1.90 | 200-d Avg | 2.52 | 1yr Est | 34.80 |
ANVS News
Roth Capital analyst Boobalan Pachaiyappan initiates coverage on Annovis Bio (NYSE:ANVS) with a B
Gainers Catheter Precision (AMEX:VTAK) shares moved upwards by 34.7% to $0.96 during Tuesday's
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage
Pivotal Phase 3 trial enrolls 850 patients, exceeding original projections Study completion on track
MALVERN, Pa., July 01, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
MALVERN, Pa., May 26, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Each warrant will be exercisable for one share of common stock at an exercise price of $2.25 per sha
MALVERN, Pa., May 20, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Shares of 8x8 Inc (NASDAQ: EGHT) jumped 13.3% in pre-market trading after reporting better-than-expe
MALVERN, Pa., May 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.63) per share which missed the analyst cons
Phase 3 AD trial: 85% of patients enrolled; full enrollment on track in summer 2026 PD open-label ex
MALVERN, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Com
Buntanetap improved cognition in pTau217-positive early AD patientsThe drug reduced neurotoxic prote
Buntanetap improved cognition in pTau217-positive early AD patients The drug reduced neurotoxic prot
Financing secures path to first NDA submission for buntanetap6-Month symptomatic data readout antici
MALVERN, Pa., April 10, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., April 09, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
Annovis Bio, Inc. (NYSE: ANVS - Get Free Report) Director Michael Hoffman bought 713,800 shares of t
Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a Phase 3 clinical-stage
MALVERN, Pa., April 02, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., March 31, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
NeuroRPM, a digital health company focused on Parkinson's disease monitoring, today announced th
MALVERN, Pa., March 19, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
NeuroRPM's AI-enabled Apple Watch-based platform will provide continuous digital biomarker monitorin
Annovis Bio (NYSE:ANVS) reported quarterly losses of $(0.39) per share which missed the analyst cons
MALVERN, Pa., March 16, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “C
MALVERN, Pa., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
Enrollment will begin in January 2026 Participants will be treated with buntanetap for 36 months The
MALVERN, Pa., Dec. 16, 2025 (GLOBE NEWSWIRE) -- Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Co
On Wednesday, 311 stocks hit new 52-week lows.
During Thursday, 849 stocks hit new 52-week lows.